Werbrouck E, De Hertogh G, Sagaert X, Coremans G, Willekens H, Demedts I, Bisschops R
Department of General Medical Oncology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
United European Gastroenterol J. 2016 Oct;4(5):663-668. doi: 10.1177/2050640615626320. Epub 2016 Jan 6.
Endoscopic resection (ER) with or without ablation is the first choice treatment for early Barrett's neoplasia. Adequate staging is important to assure a good oncological outcome.
The purpose of this study was to investigate the diagnostic accuracy of pre-operative biopsies in patients who undergo ER for high-grade dysplasia (HGD) or early adenocarcinoma (EAC) in Barrett's oesophagus (BE) and the cardia.
Between November 2005-May 2012, 142 ERs performed in 137 patients were obtained. Worst pre-ER and ER histology were compared. Upgrading/downgrading was defined as any more/less severe histological grading on the ER specimen.
The accuracy of pre-ER biopsies in predicting final histology was 61%. ER changed the pre-treatment diagnosis in 55 of the 142 procedures (39%) with downgrading in 23 cases (16%) and upgrading from HGD to T1a or T1b in 32 cases (23%). In the majority of upgraded cases, a visible lesion according to the Paris classification could be detected (26/32, 81%).
The diagnostic accuracy of oesophageal biopsies alone in predicting final pathology in Barrett's dysplasia is only 61%. The majority of upgraded lesions are detectable. When ablative therapy is considered in HGD Barrett's dysplasia a meticulous inspection for and removal of all small visible lesions is mandatory.
内镜切除(ER)联合或不联合消融是早期巴雷特肿瘤形成的首选治疗方法。充分分期对于确保良好的肿瘤学结局很重要。
本研究的目的是调查在巴雷特食管(BE)和贲门处因高级别异型增生(HGD)或早期腺癌(EAC)接受ER治疗的患者术前活检的诊断准确性。
2005年11月至2012年5月期间,获取了137例患者进行的142次ER治疗情况。比较ER治疗前最差的活检结果与ER后的组织学结果。升级/降级定义为ER标本上组织学分级更严重/更轻。
ER治疗前活检预测最终组织学结果的准确性为61%。在142例手术中,有55例(39%)ER改变了治疗前诊断,其中23例(16%)降级,32例(23%)从HGD升级为T1a或T1b。在大多数升级病例中,可检测到巴黎分类中可见的病变(26/32,81%)。
仅食管活检预测巴雷特异型增生最终病理结果的诊断准确性仅为61%。大多数升级病变是可检测到的。当考虑对HGD巴雷特异型增生进行消融治疗时,必须仔细检查并切除所有小的可见病变。